Gordon Alton

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

J. Jean Cui, Michelle Tran‐Dubé, Hong Shen et al. · Journal of Medicinal Chemistry · 2011 · 922 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

Helen Y. Zou, Qiuhua Li, Joseph H. Lee et al. · Cancer Research · 2007 · 750 citations · Full text

Medicine, Medicinal Chemistry, Oncology +16

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

James G. Christensen, Helen Y. Zou, Maria E. Arango et al. · Molecular Cancer Therapeutics · 2007 · 647 citations

Medicine, Oncology, Pharmacology +17

Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.

R Niehues, Martin Hasilik, Gordon Alton et al. · Journal of Clinical Investigation · 1998 · 428 citations · Full text

Life Sciences, Biochemistry, Pathobiology +11

Identification of a Structural Determinant Necessary for the Localization and Function of Estrogen Receptor α at the Plasma Membrane

Mahnaz Razandi, Gordon Alton, Ali Pedram et al. · Molecular and Cellular Biology · 2003 · 316 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +17